For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease. Brought together some of the foremost basic science and clinical researchers Part of the renowned Advances in Pharmacology Serial Discussion of some of the new frontiers in the development of targeted cancer therapy
To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009.
Workshop Summary Institute of Medicine, Board on Health Care Services, National Cancer Policy Forum Margie Patlak, ... This screening can identify patients that have any mutations in HER2 who can then enter the neratinib trial.
This unique book provides a thorough overview of developing molecular cancer diagnostic assays, which are the prerequisites for optimal solutions within personalized cancer medicine.
A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in ...
The book says that a new data network that integrates emerging research on the molecular makeup of diseases with clinical data on individual patients could drive the development of a more accurate classification of diseases and ultimately ...
Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently ...
Lastly, the book discusses current and potential future applications of pharmacogenomics in clinical cancer therapy and cancer drug development. This book concisely describes the role of omics in precision medicine for cancer therapies.
Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells.
Representing the first book to investigate how personalised cancer medicine is reshaping the futures of cancer patients, carers and professionals in uneven and partial ways, this book makes an essential contribution to our knowledge of ...
With its careful balance of current and future approaches, this handbook is a prime knowledge source for every drug developer, and one that will remain up to date for some time to come.